rapcabtagene autoleucel (YTB323) Clinical Trials

2 actively recruiting trials

Pipeline

Phase 1/2: 2

Top Sponsors

Novartis Pharmaceuticals2

Indications

Multiple Sclerosis2
Relapsing Multiple Sclerosis1
Progressive Multiple Sclerosis1

Other2 trials

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

Phase 1/2

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.